Stock listing

NASDAQ:FHTX Foghorn Therapeutics Inc. Stock

Home listing (NASDAQ) of Foghorn Therapeutics Inc.

Follow Foghorn Therapeutics Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:FHTX

$1.72 USD -0.07 (-3.9%)

Close on Nov 20, 2026

Past year -62.5% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$1.66 – $1.80 USDNov 20, 2026
Volume
919,929 sharesNov 20, 2026
Market cap
$103.1M USDAt the close on Nov 20, 2026 · price × 59.96M shares outstanding
52-week range
$1.66 – $7.61 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$2.49M USDMedian day 529,113 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Foghorn Therapeutics Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:FHTX · Home$1.72 USD-0.07 (-3.9%)919,929$1.74$1.80$1.66$1.79Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:FHTX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.72-0.07-3.9%$1.74$1.80$1.66919,929
$1.79-0.04-2.2%$1.79$1.82$1.75529,113
$1.83+0.04+2.2%$1.81$1.85$1.731,762,228
$1.79-0.28-13.5%$2.05$2.05$1.765829,189
$2.07+0.02+1.0%$2.04$2.08$1.94534,219
$2.05-0.04-1.9%$2.07$2.08$1.95579,935
$2.09+0.19+10.0%$1.95$2.10$1.883761,430
$1.90-0.14-6.9%$2.02$2.03$1.845719,280
$2.04+0.17+9.1%$2.08$2.12$1.891,393,839
$1.87-0.035-1.8%$1.87$1.935$1.795970,036
$1.905-0.195-9.3%$2.10$2.10$1.801,008,456
$2.10-0.03-1.4%$2.19$2.28$2.10673,574
$2.130.000.0%$2.15$2.21$2.08624,747
$2.13+0.05+2.4%$2.07$2.15$1.97715,135
$2.08-0.01-0.5%$2.08$2.09$2.005555,607
$2.09-0.04-1.9%$2.16$2.20$2.06396,983
$2.13+0.08+3.9%$2.04$2.13$2.03483,346
$2.050.000.0%$2.04$2.09$1.99874,690
$2.05+0.05+2.5%$1.99$2.06$1.93509,734
$2.00-0.01-0.5%$1.97$2.035$1.90486,822
$2.01-0.03-1.5%$2.00$2.09$1.985301,051
$2.04+0.03+1.5%$2.02$2.10$1.99819,594
$2.01+0.14+7.5%$1.87$2.065$1.87555,099
$1.87+0.02+1.1%$1.81$1.91$1.80440,851
$1.85-0.04-2.1%$1.81$1.90$1.81981,304
$1.89+0.04+2.2%$1.87$1.91$1.82349,343
$1.850.000.0%$1.85$1.89$1.801,071,894
$1.85-0.10-5.1%$1.945$1.95$1.84851,222
$1.95-0.05-2.5%$1.98$2.00$1.94586,299
$2.00+0.01+0.5%$1.96$2.081$1.945646,951
$1.99-0.10-4.8%$2.05$2.14$1.8851,228,058
$2.09+0.12+6.1%$1.92$2.15$1.906917,105
$1.97-0.03-1.5%$2.00$2.02$1.835984,692
$2.00-0.02-1.0%$2.03$2.12$1.98987,959
$2.02-0.90-30.8%$2.91$2.91$1.992,546,614
$2.92-0.65-18.2%$2.08$3.21$1.7913,378,300
$3.57+0.05+1.4%$3.55$3.60$3.50419,958
$3.520.000.0%$3.53$3.58$3.46376,219
$3.52+0.02+0.6%$3.49$3.62$3.40337,374
$3.50-0.10-2.8%$3.61$3.66$3.465525,425
$3.60-0.27-7.0%$3.83$3.85$3.55518,520
$3.87-0.37-8.7%$4.12$4.21$3.851,795,706
$4.24+0.09+2.2%$4.21$4.32$4.15328,885
$4.15+0.01+0.2%$4.16$4.19$4.07188,405
$4.14-0.06-1.4%$4.21$4.25$4.07502,030
$4.20+0.03+0.7%$4.27$4.324$4.13246,007
$4.17+0.05+1.2%$4.17$4.23$4.08354,921
$4.12-0.24-5.5%$4.35$4.38$4.09467,622
$4.36-0.06-1.4%$4.415$4.56$4.33399,648
$4.42-0.07-1.6%$4.54$4.62$4.37289,127
$4.49-0.18-3.9%$4.65$4.65$4.46396,829
$4.67-0.16-3.3%$4.79$4.895$4.66199,623
$4.83-0.09-1.8%$4.81$4.91$4.66219,642
$4.92+0.05+1.0%$4.81$5.00$4.70266,014
$4.87-0.30-5.8%$5.16$5.21$4.84442,157
$5.17-0.52-9.1%$5.75$5.89$5.032956,827
$5.69-0.05-0.9%$5.63$5.76$5.45218,800
$5.74-0.26-4.3%$5.96$5.965$5.725305,574
$6.00-0.22-3.5%$6.17$6.24$5.96370,707
$6.22-0.47-7.0%$6.68$6.80$6.08433,044
$6.69-0.16-2.3%$6.85$6.85$6.51318,860
$6.85-0.02-0.3%$6.90$7.289$6.82293,959
$6.87-0.20-2.8%$7.35$7.35$6.57402,922
$7.07+0.06+0.9%$7.10$7.348$6.95536,547
$7.01-0.05-0.7%$6.93$7.61$6.891,326,593
Ticker
NASDAQ:FHTX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Foghorn Therapeutics Inc. news

Foghorn Therapeutics Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
16 in the last 12 months · 30 in all · newest Nov 9, 2026 · oldest 2025
Decks
54 decks · latest Nov 9, 2026

Where Foghorn Therapeutics Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:FHTX · Home listing · This pageNASDAQUnited StatesUSD
BOATS:FHTXBOATSUnited StatesUSD

Valuation

EV/sales −0.1× against a median of 128×: the lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$9.22M USD
P/E
10.9×
EV/sales
−0.1×
EV/EBITDA
−2.5×
Price/book
Negative equity
Gross margin
Not reported
Operating margin
2.1%
Net margin
8.4%
Debt to equity
Negative equity
Beta vs S&P 500
1.57

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Foghorn Therapeutics Inc. · NASDAQ:FHTXUS$103.1M−US$9.22M10.9×−0.1×−2.5×n/a8.4%n/a1.57
Nykode Therapeutics ASA · OSL:NYKDUS$107.0MUS$62.24Mn/an/an/a1.3×n/a0.0×n/a
JW (Cayman) Therapeutics Co. Ltd. · HKEX:2126US$105.3MUS$84.67Mn/a2.0×n/a1.6×−195.8%0.6×n/a
Genelux Corporation · NASDAQ:GNLXUS$104.3MUS$93.85Mn/a11,732×n/a11.4×n/a0.0×1.52
Cardiol Therapeutics Inc. Class A · TSX:CRDLUS$103.4MUS$83.06Mn/an/an/a5.4×n/a0.0×1.45
Heidelberg Pharma AG · XETR:HPHAUS$103.1MUS$81.71Mn/a8.0×n/an/a−320.9%n/an/a
Vivani Medical, Inc. · NASDAQ:VANIUS$102.8MUS$88.24Mn/an/an/a7.8×n/a0.0×0.93
Paradigm Biopharmaceuticals Ltd. · ASX:PARUS$101.7MUS$96.41Mn/a1,816×n/a44.2×n/a2.2×n/a
Innate Pharma SA Class A · EURONEXT:IPHUS$101.4MUS$111.7Mn/a36.5×n/an/an/an/an/a
BRIM Biotechnology, Inc. · TWSE:6885US$100.3MUS$70.70Mn/a220×n/a2.1×n/a0.0×n/a
Minerva Neurosciences, Inc · NASDAQ:NERVUS$99.67MUS$22.73Mn/an/an/an/an/an/a1.68
Median of the othersUS$103.0MUS$83.87M128×5.4×−258.3%0.0×1.49

Forecasts

5 strong buy · 5 hold · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
4.17 USD · Analysts' mean
EPS, year to Dec 2026
-0.88 · 6 analysts
Revenue, year to Dec 2026
32.03M · 7 analysts

Team and board

Officers

OfficerRole
Adrian GottschalkPresident & CEO
Ryan MaynardChief Financial Officer
Neil GallagherMost recently President, Head of Research & Development, Syndax Pharmaceuticals
Tom LynchPresident & Director, Fred Hutchinson Cancer Center
Michael LaCasciaChief Legal Officer
Karin HellsvikChief of Staff to the CEO, VP, Head of Corporate Affairs, Investor Relations, Operations
Alena RevaVP, Total Rewards & People Operations
Andrew GermainVP, Legal
Dan DinuVP, Information Technology
Danette DanielsVP, Protein Degrader Platform
Gromek SmolenVP, Biology
Kevin WilsonVP, Chemistry
Michael Garcia-WebbVP, Program Executive, Chief of Staff Research
Saurabh SewakVP, New Products & Commercial Strategy
Alfonso Quintás-CardamaChief Medical Officer
Carlos CostaChief People Officer
Cigall KadochScientific Advisor to the Board of Directors; Founder, Foghorn Therapeutics
Doug ColeFounder, Foghorn Therapeutics; Managing Partner, Flagship Pioneering
Gerald CrabtreeFounder, Foghorn Therapeutics David Korn Professor, Stanford University Medical School Investigator, Howard Hughes Medical Institute
Lynne ParshallDirector, Ionis Pharmaceuticals
Michael MendelsohnFounder, Board Director, & Chief Strategy Officer, Cardurion Pharmaceuticals
Scott BillerExecutive Venture Partner, Google Ventures (GV)
Simba GillExecutive Chairman, Serina Therapeutics and Sensorium Therapeutics
Steven BellonChief Scientific Officer
Stuart DutyMost recently served as Senior Managing Director at Guggenheim Securities, LLC

Board

DirectorRole
Charles SawyersInvestigator, Howard Hughes Medical Institute Marie-Josée and Henry Kravis Chair in Human Oncology and Pathogenesis and Chairman, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Canc
Simba GillExecutive Chairman, Serina Therapeutics and Sensorium Therapeutics
Tom LynchPresident & Director, Fred Hutchinson Cancer Center

Events

QuarterResultsShare move
Q3 2026Nov 9, 2026 · Before open+9.1%
Q2 2026Aug 6, 2026 · Before open+14.1%
Q1 2026May 7, 2026 · Before open−10.3%
Q4 2025Mar 5, 2026+1.9%
Q3 2025Nov 5, 2025 · Before open+13.3%
Q2 2025Aug 5, 2025 · Before open−2.7%
Q1 2025May 5, 2025 · Before open−8.5%
Q4 2024Mar 6, 2025 · After close+0.4%
Q3 2024Nov 4, 2024 · After close+8.5%
Q2 2024Aug 8, 2024 · Before open+4.0%
All 20 quarters
QuarterResultsShare move
Q1 2024May 6, 2024 · Before open−2.7%
Q4 2023Mar 7, 2024 · Before open+0.6%
Q3 2023Nov 2, 2023 · Before open+7.1%
Q2 2023Aug 4, 2023 · Before open−0.5%
Q1 2023May 8, 2023 · Before open−10.3%
Q4 2022Mar 9, 2023 · After close+0.8%
Q3 2022Nov 8, 2022 · After close−8.5%
Q2 2022Aug 9, 2022 · After close+3.1%
Q1 2022May 9, 2022 · After close−2.1%
Q4 2021Mar 10, 2022 · After close+10.8%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2026)Investor deck37 slidesNov 9, 2026
Investor Presentation (August 2026)Investor deck64 slidesAugust 2026
Investor Presentation (May 2026)Investor deck64 slidesMay 7, 2026
Investor Presentation (April 2026)Investor deck64 slidesApr 21, 2026
AACR 2026Conference14 slidesApril 2026
AACR April 2026Conference24 slidesApril 2026
Investor Presentation (March 2026)Investor deck64 slidesMar 11, 2026
Investor Presentation (January 2026)Investor deck63 slidesJan 12, 2026
Investor Presentation (November 2025)Investor deck80 slidesNov 7, 2025
Investor Presentation (November 2025)Investor deck75 slidesNov 5, 2025
Show 50 decks
DeckKindSlidesDate
Technical Presentation (October 2025)Technical53 slidesOct 30, 2025
Investor Presentation (September 2025)Investor deck62 slidesSep 2, 2025
Investor Presentation (August 2025)Investor deck62 slidesAug 5, 2025
Investor Presentation (May 2025)Investor deck63 slidesMay 14, 2025
Investor Presentation (April 2025)Investor deck63 slidesApr 28, 2025
Technical Presentation (April 2025)Technical37 slidesApr 28, 2025
Investor Presentation (March 2025)Investor deck51 slidesMar 24, 2025
Investor Presentation (February 2025)Investor deck53 slidesFeb 3, 2025
Investor Presentation (January 2025)Investor deck48 slidesJan 13, 2025
Investor Presentation (December 2024)Investor deck45 slidesDec 16, 2024
Investor Presentation (November 2024)Investor deck59 slidesNov 4, 2024
Investor Presentation (October 2024)Investor deck59 slidesOct 10, 2024
Investor Presentation (August 2024)Investor deck59 slidesAug 8, 2024
Investor Presentation (June 2024)Investor deck59 slidesJun 3, 2024
Investor Presentation (May 2024)Investor deck58 slidesMay 23, 2024
Investor Presentation (May 2024)Investor deck44 slidesMay 6, 2024
Investor Presentation (April 2024)Investor deck43 slidesApr 9, 2024
Corporate Update (April 2024)Corporate update32 slidesApr 9, 2024
AACR Annual Meeting 2024Conference24 slidesApril 2024
Investor Presentation (March 2024)Investor deck37 slidesMar 7, 2024
Investor Presentation (February 2024)Investor deck35 slidesFeb 8, 2024
Investor Presentation (January 2024)Investor deck35 slidesJan 8, 2024
Investor Presentation (November 2023)Investor deck35 slidesNov 2, 2023
Investor Presentation (September 2023)Investor deck64 slidesSep 8, 2023
Investor Presentation (August 2023)Investor deck65 slidesAug 4, 2023
Investor Presentation (June 2023)Investor deck65 slidesJun 28, 2023
Investor Presentation (June 2023)Investor deck70 slidesJun 5, 2023
Investor Presentation (May 2023)Investor deck56 slidesMay 8, 2023
Cambridge Health Institute 18th Annual Drug Discovery Chemistry Meeting (April 2023)Conference24 slidesApr 13, 2023
Technical Presentation (April 2023)Technical16 slidesApr 13, 2023
Technical Presentation (April 2023)Technical14 slidesApril 2023
Investor Presentation (March 2023)Investor deck65 slidesMar 9, 2023
Investor Presentation (March 2023)Investor deck65 slidesMar 8, 2023
Investor Presentation (January 2023)Investor deck62 slidesJan 9, 2023
Investor Presentation (November 2022)Investor deck56 slidesNov 8, 2022
Investor Presentation (October 2022)Investor deck56 slidesOct 26, 2022
Investor Presentation (August 2022)Investor deck50 slidesAug 23, 2022
Investor Presentation (June 2022)Investor deck50 slidesJun 8, 2022
Investor Presentation (May 2022)Investor deck48 slidesMay 19, 2022
Investor Presentation (December 2021)Investor deck48 slidesDec 13, 2021

This page holds 50 of 54 decks. Open Decks

Open Decks

Financings

RaiseDate
Registered direct offering of common stock, pre-funded warrants and series warrants
Closed: US$50M raised · US$6.71 a share · Warrants at US$13.42
Buyers: BVF Partners; Deerfield Management; Flagship Pioneering (founding investor)
Use of proceeds: Continued investment in the pipeline; extends cash runway into the first half of 2028
Jan 13, 2026

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$16.00 a share on Oct 22, 2020.

Price
US$16.00 a share
Shares offered
7,500,000 shares of common stock
Offering size
US$120 million
Underwriters' option
Up to 1,125,000 more shares
Underwriters
Goldman Sachs & Co. LLC, Morgan Stanley, Cowen, Wedbush PacGrow · In the order on the cover
Shares delivered
On or about Oct 27, 2020

Steps

StepWhen
Draft sent to the SEC in confidenceAug 28, 2020
Filed publiclyOct 2, 2020
Amended twiceNewest Oct 22, 2020
Shares registered with an exchangeOct 19, 2020
Declared effective by the SECOct 22, 2020
Final prospectus, with the priceOct 23, 2020

Open IPO · From the cover of the final prospectus (424B4) filed Oct 23, 2020

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue30.9M22.6M34.2M19.2M1.32M430.0K00
Cost of revenue3.33M3.12M109.7M19.2K7.51M57.7M1.79M379.0K
Gross profit27.6M22.6M34.2M19.2M1.32M-57.3M-1.79M-379.0K
Research and development85.5M94.5M109.7M105.6M80.3M57.7M44.4M21.2M
Selling, general and administrative27.6M28.4M32.4M30.7M21.7M11.2M6.72M4.82M
Operating income-86.4M-102.7M-107.9M-117.1M-100.7M-68.5M-51.1M-26.0M
Depreciation and amortization3.33M3.12M3.45M3.32M3.23M1.33M693.0K379.0K
EBITDA-83.1M-99.6M-104.5M-113.8M-97.5M-67.2M-50.4M-25.7M
Interest expense11.6M1.91M979.0K540.0K371.0K
Income before tax-74.3M-86.6M-94.2M-108.9M-101.3M-68.8M-51.1M-26.3M
Income tax004.23M01.91M0083.0K
Net income-74.3M-86.6M-98.4M-108.9M-101.3M-68.8M-51.1M-26.3M
Earnings per share, basic-1.18-1.58-2.34-2.62-2.73-6.23-12.20-1.34
Earnings per share, diluted-1.18-1.58-2.34-2.62-2.73-6.23-12.20

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash and equivalents80.9M55.5M80.3M52.2M101.1M92.8M15.0M40.0M
Short-term investments78.0M188.3M153.7M293.6M53.2M93.0M
Receivables2.38M300.0M842.0K
Inventory-353.2M
Current assets163.2M249.6M240.2M351.4M459.6M190.7M16.9M40.4M
Property, plant and equipment49.4M56.1M19.5M2.68M2.09M
Total assets198.1M284.0M285.9M404.9M519.8M255.6M22.3M43.1M
Accounts payable4.27M3.79M6.26M5.41M3.82M3.68M3.44M2.01M
Current liabilities59.7M67.0M58.4M55.2M48.7M18.8M12.7M3.46M
Long-term debt019.7M11.0M7.03M
Total debt41.3M37.1M45.1M51.5M019.7M15.1M7.03M
Total liabilities306.6M329.5M363.1M404.8M422.9M109.4M23.8M82.3M
Shareholders' equity-108.5M-45.5M-77.2M112.0K96.9M146.2M-88.0M-39.3M
Shares outstanding56.7M55.6M42.3M41.8M41.3M36.8M4.87M19.6M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations-86.1M-100.4M-118.1M193.6M-50.3M-31.3M-46.3M-22.6M
Capital spending-50.0K-906.0K-1.22M-1.21M-3.31M-16.2M-968.0K-1.54M
Free cash flow-86.1M-101.3M-119.3M192.4M-53.6M-47.5M-47.3M-24.2M
Cash from investing112.0M-29.9M144.4M-244.3M36.2M-108.9M-964.0K-1.54M
Cash from financing1.02M105.4M1.78M1.76M22.4M217.5M24.0M51.8M
Share buybacks1.76M43.6M123.3M
Change in cash27.0M-24.9M28.1M-48.9M8.34M77.3M-23.3M27.6M

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 9, 2026Quarterly reportSEC
8-K · Current reportNov 9, 2026ResultsSEC
3 · Initial statement of ownershipOct 5, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 5, 2026Big-stake noticeSEC
8-K · Current reportOct 1, 2026Current reportSEC
10-Q · Quarterly reportAug 6, 2026Quarterly reportSEC
8-K · Current reportAug 6, 2026ResultsSEC
4 · Change in ownershipJun 25, 2026Insider tradeSEC
4 · Change in ownershipJun 25, 2026Insider tradeSEC
4 · Change in ownershipJun 25, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipJun 25, 2026Insider tradeSEC
4 · Change in ownershipJun 25, 2026Insider tradeSEC
4 · Change in ownershipJun 25, 2026Insider tradeSEC
4 · Change in ownershipJun 25, 2026Insider tradeSEC
4 · Change in ownershipJun 25, 2026Insider tradeSEC
4 · Change in ownershipJun 25, 2026Insider tradeSEC
8-K · Current reportJun 24, 2026Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 14, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 7, 2026Quarterly reportSEC
8-K · Current reportMay 7, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 6, 2026Big-stake noticeSEC
ARS · Annual report to shareholdersApr 30, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 30, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 30, 2026Meeting noticeSEC
8-K · Current reportApr 21, 2026Current reportSEC
4 · Change in ownershipApr 13, 2026Insider tradeSEC
S-8 · Registration statement for employee plansMar 26, 2026Offer documentSEC
10-K · Annual reportMar 11, 2026Annual reportSEC
8-K · Current reportMar 11, 2026ResultsSEC
4 · Change in ownershipFeb 24, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 24, 2026Insider tradeSEC
8-K · Current reportFeb 23, 2026Management or board changeSEC
4 · Change in ownershipFeb 6, 2026Insider tradeSEC
4 · Change in ownershipFeb 2, 2026Insider tradeSEC
4 · Change in ownershipFeb 2, 2026Insider tradeSEC
4 · Change in ownershipFeb 2, 2026Insider tradeSEC
4 · Change in ownershipFeb 2, 2026Insider tradeSEC
4 · Change in ownershipFeb 2, 2026Insider tradeSEC
4 · Change in ownershipJan 15, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJan 13, 2026Big-stake noticeSEC
424B5 · ProspectusJan 12, 2026Offer documentSEC
8-K · Current reportJan 12, 2026ResultsSEC
8-K · Current reportDec 4, 2025Management or board changeSEC
4 · Change in ownershipNov 17, 2025Insider tradeSEC
8-K · Current reportNov 7, 2025Current reportSEC
10-Q · Quarterly reportNov 5, 2025Quarterly reportSEC
8-K · Current reportNov 5, 2025ResultsSEC
8-K · Current reportOct 30, 2025Current reportSEC
8-K · Current reportSep 2, 2025Current reportSEC
10-Q · Quarterly reportAug 5, 2025Quarterly reportSEC
8-K · Current reportAug 5, 2025ResultsSEC
8-K · Current reportJul 1, 2025Material contractSEC
4 · Change in ownershipJun 17, 2025Insider tradeSEC
4 · Change in ownershipJun 17, 2025Insider tradeSEC
4 · Change in ownershipJun 17, 2025Insider tradeSEC
4 · Change in ownershipJun 17, 2025Insider tradeSEC
4 · Change in ownershipJun 17, 2025Insider tradeSEC
4 · Change in ownershipJun 17, 2025Insider tradeSEC
4 · Change in ownershipJun 17, 2025Insider tradeSEC
8-K · Current reportJun 17, 2025Meeting outcomeSEC
10-Q · Quarterly reportMay 14, 2025Quarterly reportSEC
8-K · Current reportMay 14, 2025ResultsSEC
ARS · Annual report to shareholdersMay 5, 2025Annual reportSEC
DEFA14A · Additional proxy materialMay 5, 2025Meeting noticeSEC
DEF 14A · Proxy statementMay 5, 2025Meeting noticeSEC
4 · Change in ownershipMay 2, 2025Insider tradeSEC
4 · Change in ownershipMay 2, 2025Insider tradeSEC
3 · Initial statement of ownershipMay 2, 2025Insider tradeSEC
3 · Initial statement of ownershipMay 2, 2025Insider tradeSEC
8-K · Current reportMay 1, 2025Management or board changeSEC
8-K · Current reportApr 28, 2025Current reportSEC
4 · Change in ownershipApr 28, 2025Insider tradeSEC
4 · Change in ownershipApr 10, 2025Insider tradeSEC
8-K · Current reportMar 24, 2025Current reportSEC
8-K · Current reportMar 20, 2025Current reportSEC
424B5 · ProspectusMar 20, 2025Offer documentSEC
10-K · Annual reportMar 6, 2025Annual reportSEC
8-K · Current reportMar 6, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2025Big-stake noticeSEC
8-K · Current reportFeb 3, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveFeb 3, 2025Other filingsSEC
CORRESP · Letter to the SECJan 29, 2025Other filingsSEC
UPLOAD · Letter from the SECJan 29, 2025Other filingsSEC
4 · Change in ownershipJan 24, 2025Insider tradeSEC
4 · Change in ownershipJan 24, 2025Insider tradeSEC
4 · Change in ownershipJan 24, 2025Insider tradeSEC
4 · Change in ownershipJan 24, 2025Insider tradeSEC
4 · Change in ownershipJan 24, 2025Insider tradeSEC
4 · Change in ownershipJan 24, 2025Insider tradeSEC
4 · Change in ownershipJan 24, 2025Insider tradeSEC
S-3 · Registration statementJan 24, 2025Offer documentSEC
S-8 · Registration statement for employee plansJan 24, 2025Offer documentSEC
8-K · Current reportJan 24, 2025Current reportSEC
8-K · Current reportJan 13, 2025ResultsSEC
4 · Change in ownershipDec 30, 2024Insider tradeSEC
8-K · Current reportDec 30, 2024Management or board changeSEC
8-K · Current reportDec 16, 2024Current reportSEC
10-Q · Quarterly reportNov 4, 2024Quarterly reportSEC
8-K · Current reportNov 4, 2024ResultsSEC
8-K · Current reportOct 10, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedOct 8, 2024Big-stake noticeSEC
4 · Change in ownershipSep 24, 2024Insider tradeSEC
SC 13G · Big-stake noticeSep 20, 2024Big-stake noticeSEC
4 · Change in ownershipSep 20, 2024Insider tradeSEC
4 · Change in ownershipSep 18, 2024Insider tradeSEC
144 · Notice of proposed saleSep 16, 2024Other filingsSEC
4 · Change in ownershipSep 11, 2024Insider tradeSEC
144 · Notice of proposed saleSep 9, 2024Other filingsSEC
4 · Change in ownershipSep 4, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 4, 2024Insider tradeSEC
424B5 · ProspectusAug 8, 2024Offer documentSEC
10-Q · Quarterly reportAug 8, 2024Quarterly reportSEC
8-K · Current reportAug 8, 2024ResultsSEC
4 · Change in ownershipJun 28, 2024Insider tradeSEC
4 · Change in ownershipJun 28, 2024Insider tradeSEC
4 · Change in ownershipJun 28, 2024Insider tradeSEC
4 · Change in ownershipJun 28, 2024Insider tradeSEC
4 · Change in ownershipJun 28, 2024Insider tradeSEC
4 · Change in ownershipJun 28, 2024Insider tradeSEC
4 · Change in ownershipJun 28, 2024Insider tradeSEC
4 · Change in ownershipJun 28, 2024Insider tradeSEC
8-K · Current reportJun 26, 2024Meeting outcomeSEC
4 · Change in ownershipJun 24, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedJun 10, 2024Big-stake noticeSEC
8-K · Current reportJun 3, 2024Current reportSEC
SC 13G · Big-stake noticeMay 30, 2024Big-stake noticeSEC
4 · Change in ownershipMay 24, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedMay 24, 2024Big-stake noticeSEC
3 · Initial statement of ownershipMay 24, 2024Insider tradeSEC
8-K · Current reportMay 23, 2024Current reportSEC
8-K · Current reportMay 22, 2024Material contractSEC
424B5 · ProspectusMay 20, 2024Offer documentSEC
8-K · Current reportMay 20, 2024Current reportSEC
8-K · Current reportMay 6, 2024Current reportSEC
10-Q · Quarterly reportMay 6, 2024Quarterly reportSEC
S-8 · Registration statement for employee plansMay 6, 2024Offer documentSEC
8-K · Current reportMay 6, 2024ResultsSEC
ARS · Annual report to shareholdersMay 3, 2024Annual reportSEC
DEFA14A · Additional proxy materialMay 3, 2024Meeting noticeSEC
DEF 14A · Proxy statementMay 3, 2024Meeting noticeSEC
4 · Change in ownershipApr 17, 2024Insider tradeSEC
3 · Initial statement of ownershipApr 17, 2024Insider tradeSEC
8-K · Current reportApr 16, 2024Management or board changeSEC
8-K · Current reportApr 9, 2024Current reportSEC
4 · Change in ownershipMar 12, 2024Insider tradeSEC
8-K · Current reportMar 7, 2024ResultsSEC
10-K · Annual reportMar 7, 2024Annual reportSEC
SC 13G/A · Big-stake notice, amendedFeb 9, 2024Big-stake noticeSEC
8-K · Current reportFeb 8, 2024Current reportSEC
4 · Change in ownershipJan 25, 2024Insider tradeSEC
4 · Change in ownershipJan 25, 2024Insider tradeSEC
4 · Change in ownershipJan 25, 2024Insider tradeSEC
4 · Change in ownershipJan 25, 2024Insider tradeSEC
4 · Change in ownershipJan 25, 2024Insider tradeSEC
4 · Change in ownershipJan 25, 2024Insider tradeSEC
8-K · Current reportJan 17, 2024Management or board changeSEC
4 · Change in ownershipJan 17, 2024Insider tradeSEC
8-K · Current reportJan 8, 2024Current reportSEC
8-K · Current reportJan 3, 2024Management or board changeSEC
4 · Change in ownershipDec 12, 2023Insider tradeSEC
10-Q · Quarterly reportNov 2, 2023Quarterly reportSEC
8-K · Current reportNov 2, 2023ResultsSEC
4 · Change in ownershipSep 13, 2023Insider tradeSEC
4 · Change in ownershipSep 13, 2023Insider tradeSEC
3 · Initial statement of ownershipSep 13, 2023Insider tradeSEC
8-K · Current reportSep 8, 2023Current reportSEC
8-K · Current reportAug 31, 2023Current reportSEC
4 · Change in ownershipAug 18, 2023Insider tradeSEC
4 · Change in ownershipAug 18, 2023Insider tradeSEC
144 · Notice of proposed saleAug 16, 2023Other filingsSEC
8-K · Current reportAug 10, 2023Current reportSEC
8-K · Current reportAug 8, 2023Current reportSEC
10-Q · Quarterly reportAug 4, 2023Quarterly reportSEC
8-K · Current reportAug 4, 2023ResultsSEC
8-K · Current reportJun 28, 2023Current reportSEC
4 · Change in ownershipJun 22, 2023Insider tradeSEC
4 · Change in ownershipJun 22, 2023Insider tradeSEC
4 · Change in ownershipJun 22, 2023Insider tradeSEC
4 · Change in ownershipJun 22, 2023Insider tradeSEC
4 · Change in ownershipJun 22, 2023Insider tradeSEC
4 · Change in ownershipJun 22, 2023Insider tradeSEC
4 · Change in ownershipJun 22, 2023Insider tradeSEC
4 · Change in ownershipJun 22, 2023Insider tradeSEC
8-K · Current reportJun 22, 2023Meeting outcomeSEC
8-K · Current reportJun 5, 2023Current reportSEC
4 · Change in ownershipMay 31, 2023Insider tradeSEC
S-8 · Registration statement for employee plansMay 8, 2023Offer documentSEC
10-Q · Quarterly reportMay 8, 2023Quarterly reportSEC
8-K · Current reportMay 8, 2023ResultsSEC
ARS · Annual report to shareholdersApr 28, 2023Annual reportSEC
DEFA14A · Additional proxy materialApr 28, 2023Meeting noticeSEC
DEF 14A · Proxy statementApr 28, 2023Meeting noticeSEC
8-K · Current reportApr 24, 2023Current reportSEC
10-K · Annual reportMar 9, 2023Annual reportSEC
8-K · Current reportMar 9, 2023ResultsSEC
8-K · Current reportMar 8, 2023Current reportSEC
4 · Change in ownershipFeb 22, 2023Insider tradeSEC
SC 13G/A · Big-stake notice, amendedFeb 9, 2023Big-stake noticeSEC
4 · Change in ownershipJan 30, 2023Insider tradeSEC

This page holds 200 of 356 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Foghorn Therapeutics Inc.’s releases · as of Oct 30, 2026

Common shares
59,962,650
Fully diluted
59,962,650

Fully diluted

LineSharesAs of
Common shares59,962,650Oct 30, 2026

Warrants and options

Lot
Warrants · US$13.42 · expiry not stated

Share count over time

CountShares
Oct 30, 202659,962,650

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueChange vs Jun 30Filed
Flagship Pioneering, LLC12.7M21.1%US$45.2MNo changeNov 16, 2026
Bvf Inc5.84M9.7%US$20.9MNo changeNov 16, 2026
Fidelity5.55M9.2%US$19.8M−160KNov 10, 2026
Deerfield Management Company, L.P.4.39M7.3%US$15.7MNo changeNov 16, 2026
BlackRock3.07M5.1%US$10.9M+438KNov 13, 2026
Raymond James Financial Inc2.48M4.1%US$8.85M−10,357Nov 12, 2026
Vanguard2.21M3.7%US$7.9M+136KNov 13, 2026
Euclidean Capital LLC1.57M2.6%US$5.62MNo changeNov 16, 2026
Geode Capital862K1.4%US$3.08M−49,211Nov 6, 2026
Siren, L.L.C.721K1.2%US$2.57MNo changeNov 12, 2026
Show 50 holders
HolderSharesOf the companyValueChange vs Jun 30Filed
State Street692K1.2%US$2.47M−5,179Nov 12, 2026
JPMorgan644K1.1%US$2.27M+623KNov 12, 2026
Qube Research & Technologies Ltd540K0.90%US$1.93M+337KNov 13, 2026
Renaissance Technologies432K0.72%US$1.54M+54,403Nov 12, 2026
Jacobs Levy Equity Management, Inc321K0.54%US$1.15M+15,850Nov 16, 2026
Northern Trust316K0.53%US$1.13M+6,657Nov 16, 2026
Candriam S.C.A.314K0.52%US$1.12MNo changeNov 3, 2026
Birchview Capital, LP282K0.47%US$1.01M+370Nov 13, 2026
Goldman Sachs235K0.39%US$838K+70,413Nov 16, 2026
Panagora Asset Management Inc227K0.38%US$811K+51,685Nov 12, 2026
B Group, Inc.200K0.33%US$714KNo changeNov 16, 2026
Morgan Stanley173K0.29%US$617K+80,743Nov 13, 2026
Ikarian Capital, LLC160K0.27%US$571KNewNov 16, 2026
Mackenzie151K0.25%US$540KNewNov 2, 2026
Acadian Asset Management LLC151K0.25%US$535K+112KNov 9, 2026
UBS138K0.23%US$494K+124KNov 16, 2026
Squarepoint Ops LLC137K0.23%US$491K+7,089Nov 9, 2026
Ameriprise129K0.21%US$459K−430KNov 16, 2026
Schwab127K0.21%US$454K+17,291Nov 16, 2026
SCS Capital Management LLC107K0.18%US$382KNo changeNov 12, 2026
Citadel106K0.18%US$380K−52,343Nov 16, 2026
Point72 Asset Management, L.P.106K0.18%US$379KNewNov 16, 2026
Susquehanna106K0.18%US$378KNewNov 16, 2026
DAFNA Capital Management LLC89,6590.15%US$320K−22,200Nov 16, 2026
Palumbo Wealth Management LLC88,7910.15%US$317K−2,948Nov 12, 2026
Prudential Financial Inc86,9980.15%US$311KNewNov 16, 2026
Invesco83,3130.14%US$297K+5,178Nov 12, 2026
Millennium82,2360.14%US$294K+28,727Nov 16, 2026
Hrt Financial LP79,9610.13%US$285KNewNov 13, 2026
Trexquant Investment LP79,7110.13%US$285KNewNov 16, 2026
BNY77,5750.13%US$277K−1,780Nov 5, 2026
Bridgeway Capital Management, LLC77,1000.13%US$275K−12,500Nov 16, 2026
Empowered Funds, LLC70,5000.12%US$252KNewNov 13, 2026
Gsa Capital Partners LLP68,5010.11%US$245K+38,995Nov 16, 2026
Nuveen67,0770.11%US$239K+2,038Nov 10, 2026
Lynx1 Capital Management LP61,5880.10%US$220KNo changeNov 16, 2026
Boothbay Fund Management, LLC51,1460.09%US$183KNewNov 16, 2026
Verdad Advisers, LP42,0490.07%US$150K−11,182Nov 16, 2026
Rhumbline Advisers41,8320.07%US$149K+2,250Nov 10, 2026
Bank of America41,4880.07%US$148K+15,385Nov 16, 2026

This page holds 50 of 117 holders. Open Shareholders

Funds

HolderSharesOf the companyValueChangeAs of
Fidelity Growth Company Fund1.84M3.1%US$7.86MNo changeMay 31, 2026
Vanguard Total Stock Market Index Fund1.03M1.7%US$5.01M+990Jun 30, 2026
iShares Russell 2000 ETF897K1.5%US$4.38M+106KJun 30, 2026
Fidelity Growth Company K6 Fund501K0.84%US$2.14M−6,537May 31, 2026
Vanguard Extended Market Index Fund428K0.71%US$2.09M−1,468Jun 30, 2026
Fidelity Small Cap Index Fund396K0.66%US$1.8M+55,678Jul 31, 2026
Select Biotechnology Portfolio352K0.59%US$1.5M−303KMay 31, 2026
iShares Russell 2000 Growth ETF343K0.57%US$1.67M+156KJun 30, 2026
Fidelity Series Growth Company Fund284K0.47%US$1.22M−43,400May 31, 2026
iShares Biotechnology ETF222K0.37%US$1.08M−1,392Jun 30, 2026
Show 50 holders
HolderSharesOf the companyValueChangeAs of
Fidelity Extended Market Index Fund188K0.31%US$806K+3,922May 31, 2026
Vanguard Russell 2000 Index Fund176K0.29%US$753K+11,620May 31, 2026
iShares Micro-Cap ETF122K0.20%US$597K+34,099Jun 30, 2026
Schwab Small-Cap Index Fund87,9610.15%US$398K+14,459Jul 31, 2026
Ultra-Small Company Market Fund83,0000.14%US$405K+15,000Jun 30, 2026
Master Small Cap Index Series63,9230.11%US$312KNo changeJun 30, 2026
Fidelity Total Market Index Fund62,1130.10%US$266KNo changeMay 31, 2026
Fidelity Series Total Market Index Fund56,8790.09%US$243K+7,320May 31, 2026
Small Company Growth Portfolio53,6440.09%US$262KNo changeJun 30, 2026
Nuveen Small Cap Blend Index Fund48,3220.08%US$219K+14,661Jul 31, 2026
Fidelity Nasdaq Composite Index Fund36,6290.06%US$157K+3,132May 31, 2026
EQ/2000 Managed Volatility Portfolio36,4980.06%US$178KNo changeJun 30, 2026
Fidelity Small Cap Growth Index Fund34,0150.06%US$166K+15,911Jun 30, 2026
Schwab Total Stock Market Index Fund30,0000.05%US$136KNo changeJul 31, 2026
Multi-Manager Small Cap Equity Strategies Fund28,1050.05%US$120KNo changeMay 31, 2026
Vanguard Russell 2000 Growth Index Fund21,9250.04%US$93,839+656May 31, 2026
Goldman Sachs Absolute Return Tracker Fund21,1280.04%US$103K+10,275Jun 30, 2026
LVIP State Street Small-Cap Index Fund20,0000.03%US$97,600No changeJun 30, 2026
Vanguard Balanced Index Fund19,9620.03%US$97,415No changeJun 30, 2026
Vanguard Institutional Total Stock Market Index Fund19,2680.03%US$94,028No changeJun 30, 2026
Small Cap Index Fund19,2080.03%US$93,735+733Jun 30, 2026
EQ/Small Company Index Portfolio17,6200.03%US$85,986+1,550Jun 30, 2026
Global X Russell 2000 ETF17,4330.03%US$78,971+2,385Jul 31, 2026
Nuveen Equity Index Fund14,4970.02%US$65,671No changeJul 31, 2026
Clearwater Select Equity Fund13,5840.02%US$66,290No changeJun 30, 2026
NVIT Multi-Manager Small Company Fund13,2980.02%US$64,894−5,000Jun 30, 2026
Small Cap Index Fund12,9710.02%US$55,516No changeMay 31, 2026
State Street Small/Mid Cap Equity Index Portfolio12,8000.02%US$62,464No changeJun 30, 2026
PACE Small/Medium Co Growth Equity Investments11,8590.02%US$53,721−2,617Jul 31, 2026
Invesco RAFI US 1500 Small-Mid ETF10,8140.02%US$48,987+4,265Jul 31, 2026
Small-Cap Index Portfolio10,8100.02%US$52,753No changeJun 30, 2026
ATM Small Cap Managed Volatility Portfolio10,6830.02%US$52,133No changeJun 30, 2026
NVIT Small Cap Value Fund9,7530.02%US$47,595−3,700Jun 30, 2026
EQ/AB Small Cap Growth Portfolio9,0700.02%US$44,262+1,550Jun 30, 2026
VIP Disciplined Small Cap Portfolio8,9060.01%US$43,461NewJun 30, 2026
Small Cap Equity Fund8,8830.01%US$43,349−11,410Jun 30, 2026
Vanguard Russell 2000 Value Index Fund8,3090.01%US$35,563+1,379May 31, 2026
1290 VT Micro Cap Portfolio8,2610.01%US$40,314+1,897Jun 30, 2026
Small Cap Core Fund6,6290.01%US$32,350−312Jun 30, 2026
NVIT Small Cap Index Fund6,5730.01%US$32,076No changeJun 30, 2026

This page holds 50 of 96 holders. Open Shareholders

Big stakes

HolderStakeSharesDate
Flagship Ventures Fund V, L.P.15.90%9.33MJan 9, 2026
BVF PARTNERS L P/IL14.30%8.51MOct 1, 2026
FMR LLC11.60%6.79MMar 31, 2026
Deerfield Mgmt, L.P.8.64%5.14MMar 31, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Noubar Afeyan
Other companies: Generate Biomedicines, Inc. (Chair of the Board · Since at least Feb 26, 2026); Moderna, Inc. (Director · Since at least Dec 7, 2018); BG Medicine Inc (Director · Since at least Feb 3, 2011); Omega Therapeutics Inc (Director · Jul 29, 2021 – Jun 7, 2023 · Past); Kaleido Biosciences, Inc. (Director · Feb 27, 2019 – Mar 4, 2019 · Past); Rubius Therapeutics Inc (Director · Jul 17, 2018 – May 12, 2022 · Past); Evelo Biosciences, Inc. (Director · May 8, 2018 – Jun 12, 2019 · Past); Cartesian Therapeutics, Inc. (Director · Jun 21, 2016 – Jun 21, 2016 · Past); Seres Therapeutics, Inc. (Director · Jun 25, 2015 – Jun 18, 2019 · Past); Eleven Biotherapeutics Inc (Director · Feb 5, 2014 – Mar 20, 2014 · Past); BIND Therapeutics Inc (Director · Sep 19, 2013 – Sep 25, 2013 · Past); Color Kinetics Inc (Director · Jan 3, 2006 – Aug 24, 2007 · Past); Agenus Inc. (Director · Jan 13, 2005 – Jun 7, 2007 · Past)
Director · Since at least Jan 13, 2026
Adam Koppel
Other companies: Kailera Therapeutics, Inc. (Partner, Bain Capital Life Sciences · Since at least Apr 16, 2026); Cerevel Therapeutics Holdings Inc (Director · Oct 27, 2020 – Aug 1, 2024 · Past); BCLS Acquisition Corp (Director · Oct 21, 2020 – Oct 26, 2020 · Past); Replimune Group, Inc. (Director · Jul 24, 2018 – Jul 24, 2018 · Past); Aptinyx Inc (Director · Jun 20, 2018 – May 26, 2022 · Past); Solid Biosciences Inc. (Director · Jan 25, 2018 – Jan 11, 2024 · Past); Dicerna Pharmaceuticals Inc (Director · Apr 11, 2017 – Dec 28, 2021 · Past); Trevena, Inc. (Director · Sep 17, 2014 – May 16, 2018 · Past); Biogen Inc. (EVP, Strategy and Bus. Dev. · May 15, 2014 – Jun 6, 2016 · Past); PTC Therapeutics, Inc. (Director · Jun 19, 2013 – Jan 3, 2017 · Past)
Director · Oct 22, 2020 – Dec 29, 2024 · Past
Douglas G Cole
Other companies: Sana Biotechnology, Inc. (Director · Feb 3, 2021 – Jun 6, 2024 · Past); Sigilon Therapeutics Inc (Director · Dec 3, 2020 – Aug 11, 2023 · Past); Denali Therapeutics Inc. (Director · Dec 7, 2017 – Jun 1, 2023 · Past); Quanterix Corporation (Director · Dec 6, 2017 – Jan 2, 2019 · Past); Editas Medicine, Inc. (Director · Feb 2, 2016 – Aug 17, 2017 · Past); Agios Pharmaceuticals, Inc. (Director · Jul 23, 2013 – Aug 10, 2016 · Past); Receptos Inc (Director · May 8, 2013 – Jul 17, 2013 · Past); Tetraphase Pharmaceuticals Inc (Director · Mar 19, 2013 – Mar 25, 2013 · Past); AVEO Pharmaceuticals Inc (Director · Mar 11, 2010 – May 12, 2011 · Past)
Director · Since at least Oct 22, 2020
David Schenkein
Other companies: Regeneron Pharmaceuticals, Inc. (Director · Since at least Sep 8, 2023); Prime Medicine, Inc. (Board Member · Since at least Oct 19, 2022); Denali Therapeutics Inc. (Director · Since at least Dec 7, 2017); Foundation Medicine Inc (Director · Sep 24, 2013 – Jun 16, 2016 · Past); Agios Pharmaceuticals, Inc. (Director · Jul 23, 2013 – Jun 20, 2024 · Past); Bluebird bio Inc (Director · Jun 18, 2013 – Jun 18, 2020 · Past)
General Partner, Co-leader, Agios · Until Apr 13, 2026 · Past
Lynne Parshall
Other companies: Cytokinetics, Incorporated (Director · Since at least Feb 7, 2013); Ionis Pharmaceuticals, Inc. (Director · Since at least Jan 3, 2006); Akcea Therapeutics Inc (Director · Jul 13, 2017 – Oct 12, 2020 · Past); Regulus Therapeutics Inc (Director · Oct 4, 2012 – Nov 3, 2014 · Past); Cardiodynamics International Corp (Director · Jul 20, 2006 – Aug 14, 2009 · Past)
Director, Ionis Pharmaceuticals · Since at least Aug 16, 2022
Ian Smith
Other companies: Odyssey Therapeutics, Inc. (Director · Since at least May 7, 2026); Stoke Therapeutics, Inc. (Chief Executive Officer, Director · Since at least Sep 19, 2023); Solid Biosciences Inc. (Chairman of the Board · Since at least Dec 10, 2020)
Director · Since at least Apr 27, 2021
Kristian Humer
Other companies: 4D Molecular Therapeutics, Inc. (Chief Financial Officer · Since at least Dec 9, 2025); Sensei Biotherapeutics, Inc. (Director · Jul 30, 2021 – May 21, 2025 · Past); Viridian Therapeutics, Inc. (CFO and CBO · Jul 26, 2021 – Feb 8, 2023 · Past)
Chief Financial Officer · Since at least Apr 16, 2024
Ryan Maynard
Other companies: Iovance Biotherapeutics, Inc. (Director · Since at least Feb 16, 2015); Tvardi Therapeutics, Inc. (CHIEF FINANCIAL OFFICER · Sep 12, 2022 – Feb 8, 2024 · Past); Rigel Pharmaceuticals, Inc. (EVP & CFO · May 27, 2010 – Nov 3, 2017 · Past)
Chief Financial Officer · Since at least Feb 23, 2026
Stuart Duty
Other companies: Milestone Pharmaceuticals Inc. (Independent Non-Executive Director · Since at least Jul 15, 2024); EyePoint, Inc. (Board Member · Since at least Oct 16, 2023); Achieve Life Sciences, Inc. (Director · Since at least Mar 29, 2023)
Director · Since at least May 1, 2025
Allan Reine
Other companies: Prime Medicine, Inc. (Chief Executive Officer, Director · Since at least Jan 17, 2024); Palvella Therapeutics, Inc. (Chief Financial Officer · Aug 9, 2017 – Feb 26, 2019 · Past)
Chief Financial Officer · Oct 22, 2020 – Jan 16, 2024 · Past
All 40 people
PersonSeat
Jose Baselga
Other companies: Bristol-Myers Squibb Company (Director · Mar 1, 2018 – Sep 30, 2018 · Past); Varian Medical Systems Inc (Director · Mar 1, 2017 – Feb 9, 2018 · Past)
Director · Oct 22, 2020 – Oct 22, 2020 · Past
Neil Gallagher
Other companies: Zymeworks Inc. (Director · Apr 2, 2024 – Dec 10, 2024 · Past); Syndax Pharmaceuticals, Inc. (President, Head of R&D · Apr 10, 2023 – Feb 10, 2025 · Past)
Most recently President, Head of Research & Development, Syndax Pharmaceuticals · Since at least May 1, 2025
Simba Gill
Other companies: Serina Therapeutics, Inc. (Director · Since at least Apr 12, 2024); Evelo Biosciences, Inc. (President & CEO, Director · May 8, 2018 – Nov 7, 2023 · Past)
Executive Chairman, Serina Therapeutics and Sensorium Therapeutics · Since at least Oct 22, 2020
Thomas J Lynch Jr
Other companies: Natera, Inc. (Director · Since at least Jun 2, 2026); Bristol-Myers Squibb Company (EVP & Chief Scientific Officer · Dec 12, 2017 – Apr 3, 2019 · Past)
Director · Since at least Oct 27, 2022
Alfonso Quintás-Cardama
Other companies: Tcr2 Therapeutics Inc (Chief Medical Officer · Feb 13, 2019 – Jun 1, 2023 · Past)
Chief Medical Officer · Since at least Sep 11, 2023
Michael Mendelsohn
Other companies: Cyclerion Therapeutics, Inc. (Director · Apr 1, 2019 – Jun 14, 2022 · Past)
Founder, Board Director, & Chief Strategy Officer, Cardurion Pharmaceuticals · Since at least Oct 22, 2020
Samuel Agresta
Other companies: OnKure Therapeutics, Inc. (Chief Medical Officer · Since at least Oct 4, 2024)
Chief Medical Officer · Oct 22, 2020 – Sep 11, 2023 · Past
Scott Biller
Other companies: Agios Pharmaceuticals, Inc. (Chief Scientific Officer · Jul 23, 2013 – Jun 11, 2019 · Past)
Executive Venture Partner, Google Ventures (GV) · Since at least Oct 22, 2020
Adrian GottschalkPresident & CEO · Since at least Oct 22, 2020
Alena RevaVP, Total Rewards & People Operations · Since at least Nov 5, 2026
Andrew GermainVP, Legal · Since at least Nov 5, 2026
Anna RivkinChief Business Officer · Since at least Sep 3, 2024
Carl DeciccoChief Scientific Officer · Oct 22, 2020 – Dec 9, 2021 · Past
Carlos CostaChief People Officer · Since at least Aug 1, 2022
Charles SawyersInvestigator, Howard Hughes Medical Institute Marie-Josée and Henry Kravis Chair in Human Oncology and Pathogenesis and Chairman, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Canc · Since at least Nov 5, 2026
Cigall KadochScientific Advisor to the Board of Directors; Founder, Foghorn Therapeutics · Since at least Oct 22, 2020
Dan DinuVP, Information Technology · Since at least Nov 4, 2026
Danette DanielsVP, Protein Degrader Platform · Since at least Apr 9, 2026
Doug ColeFounder, Foghorn Therapeutics; Managing Partner, Flagship Pioneering · Since at least Nov 4, 2026
Fanny CavalieChief Strategy/Bus Ops Officer · Feb 14, 2022 – Jun 21, 2024 · Past
Gerald CrabtreeFounder, Foghorn Therapeutics David Korn Professor, Stanford University Medical School Investigator, Howard Hughes Medical Institute · Since at least Nov 5, 2026
Gromek SmolenVP, Biology · Since at least Apr 9, 2026
Karin HellsvikChief of Staff to the CEO, VP, Head of Corporate Affairs, Investor Relations, Operations · Since at least Nov 3, 2026
Kevin WilsonVP, Chemistry · Since at least Nov 5, 2026
Michael Garcia-WebbVP, Program Executive, Chief of Staff Research · Since at least Nov 5, 2026
Michael LaCasciaChief Legal Officer · Since at least Nov 9, 2020
Saurabh SewakVP, New Products & Commercial Strategy · Since at least Nov 5, 2026
Steven BellonChief Scientific Officer · Since at least Apr 9, 2026
Steven F BellonChief Scientific Officer · Since at least Oct 22, 2020
Tom LynchPresident & Director, Fred Hutchinson Cancer Center · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about Foghorn Therapeutics Inc.